Perspective Therapeutics (CATX) Barclays 27th Annual Global Healthcare Conference summary

Supply chain and regulatory environment

• Tariffs have minimal impact due to domestic sourcing of key precursors and isotopes, primarily from the U.S. Department of Energy.

• No observed changes in FDA engagement or delays despite potential FDA budget cuts; FDA remains supportive of innovation.

• NIH funding cuts are causing acute operational challenges at clinical trial sites, impacting patient care and research capacity.

Manufacturing and distribution strategy

• Product shelf life for Lead-212 enables same-day or overnight distribution, with central manufacturing feasible.

• Active manufacturing sites in Iowa and New Jersey, with expansion underway in Houston, Los Angeles, and Chicago.

• Facilities are cost-efficient, leveraging chemical separation technology for isotope purification, avoiding need for on-site reactors.

Platform differentiation and clinical approach

• Lead-212 chosen for optimal half-life and therapeutic profile; paired with Lead-203 for precise dosimetry.

• Proprietary chelator technology enables targeted delivery and IP protection; platform allows tuning of biodistribution and pharmacokinetics.

• Diagnostic imaging with the therapeutic agent enables patient selection and de-risking before treatment.